<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880514</url>
  </required_header>
  <id_info>
    <org_study_id>P500-0616</org_study_id>
    <nct_id>NCT02880514</nct_id>
  </id_info>
  <brief_title>In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia</brief_title>
  <acronym>FRONTIER</acronym>
  <official_title>A Clinical Evaluation of Propel Mini Sinus Implant Placement in the Frontal Sinus Ostia Following In-office Dilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intersect ENT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intersect ENT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-blind, intra-patient controlled, multicenter trial
      with 50 subjects enrolled at up to 15 sites across the United States. Study subjects undergo
      implant placement on one side following in-office balloon dilation, while the contralateral
      side undergoes balloon dilation only and serves as a control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency Rate</measure>
    <time_frame>Day 30</time_frame>
    <description>Patency of the frontal recess/frontal sinus ostia (FSO) was evaluated on a 3-point grading scale from 0 to 2, with 0=Patent, 1=Restenosed/partially occluded, and 2=Occluded. The percentage of sinuses with patency grade 0 and 1 was used to calculate the patency rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation Score</measure>
    <time_frame>Day 30</time_frame>
    <description>Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>PROPEL Mini Sinus Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balloon Sinus Dilation Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROPEL Mini Sinus Implant</intervention_name>
    <description>Sinus implant with 370 mcg of mometasone furoate released over 30 days</description>
    <arm_group_label>PROPEL Mini Sinus Implant</arm_group_label>
    <other_name>PROPEL Mini</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon Sinus Dilation Alone</intervention_name>
    <arm_group_label>Balloon Sinus Dilation Alone</arm_group_label>
    <arm_group_label>PROPEL Mini Sinus Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient has provided written informed consent using a form approved by the reviewing
             IRB.

          -  Patient is 18 years of age or older.

          -  Patient is willing and able to comply with protocol requirements.

          -  Patient has CRS defined as sinonasal inflammation persisting for more than 12 weeks
             and complains of at least 2 of the 4 following symptoms: nasal
             blockage/obstruction/congestion, nasal blockage/obstruction/congestion, nasal
             discharge (anterior/posterior), facial pain/pressure, reduction/loss of smell

          -  CRS diagnosis confirmed by CT scan within 3 months prior to enrollment

          -  Bilateral frontal sinusitis confirmed by Lund-Mackay score of â‰¥1 on each side

          -  Post-endoscopic sinus surgery, patient has bilateral obstruction of the frontal sinus
             ostia by scarring and/or polypoid edema.

          -  Patient is a candidate for an in-office balloon dilation procedure.

          -  In the opinion of the investigator, treatment with the Propel Mini Sinus Implant as an
             adjunct to balloon sinus dilation is technically feasible and clinically indicated in
             the frontal sinus ostia.

        Exclusion Criteria:

          -  Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus of
             grade 3 or 4 unless reduced prior to randomization in the study.

          -  Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD)
             or other conditions.

          -  Known history of allergy or intolerance to corticosteroids or mometasone furoate.

          -  Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis.

          -  Active viral illness (e.g., flu, shingles).

          -  Clinical evidence of disease or condition expected to compromise survival or ability
             to complete follow-up assessments through Day 180 post-procedure.

          -  Currently participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey Silvers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madison ENT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento ENT</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT Assoicates of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Surgical Specialists</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's ENT Specialists</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica of Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison ENT</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sinus Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <results_first_submitted>June 6, 2018</results_first_submitted>
  <results_first_submitted_qc>November 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2018</results_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Frontal Sinus</keyword>
  <keyword>Balloon Dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 50 participants were recruited across 12 clinical sites.</recruitment_details>
      <pre_assignment_details>An intra-patient control design was employed where left and right frontal sinuses of each patient were randomized to the treatment or control group after successful completion of in-office balloon dilation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PROPEL Mini Sinus Implant</title>
          <description>Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) after a successful in-office balloon dilation</description>
        </group>
        <group group_id="P2">
          <title>Balloon Sinus Dilation Alone</title>
          <description>Successful in-office balloon dilation of the frontal sinus ostia (FSO) without implant placement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">A total of 50 subjects with one sinus side assigned to the treatment group</participants>
                <participants group_id="P2" count="50">A total of 50 subjects with one sinus side assigned to the control group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>This study used an intra-patient design with each participant having one sinus side randomized to the treatment group and the other to the control group.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lund-Mackay Total Score</title>
          <description>The Lund-Mackay score is a method of radiologic staging of chronic rhinosinusitis based on computed tomography (CT) where each sinus is assigned a score of 0 (no abnormality), 1 (partial opacification), or 2 (complete opacification). The overall total score is the sum of scores from 6 sinuses on each side and ranges from 0 to 24 with higher score indicating greater disease burden.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lund-MacKay Frontal Score</title>
          <description>The Lund-Mackay Frontal score is determined based on computed tomography (CT) of the frontal sinus on a 0 to 2 scale where 0 = no abnormality, 1 = partial opacification, and 2 = complete opacification. The frontal score is the sum of scores on the left and right side and ranges from 0 to 4 with higher score indicating greater disease burden.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patency Rate</title>
        <description>Patency of the frontal recess/frontal sinus ostia (FSO) was evaluated on a 3-point grading scale from 0 to 2, with 0=Patent, 1=Restenosed/partially occluded, and 2=Occluded. The percentage of sinuses with patency grade 0 and 1 was used to calculate the patency rate.</description>
        <time_frame>Day 30</time_frame>
        <population>Outcome analyzed using the intent-to-treat population, which consisted of all randomized subjects and sinuses. Patency grade for 10 sinuses (6 treatment, 4 control) were missing as clinical investigators were unable to view the frontal recess/FSO, reducing the number of evaluable subjects to 44 in the treatment group and 46 in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Placement of the Propel Mini Sinus Implant in the frontal sinus ostia (FSO) after a successful in-office balloon dilation</description>
          </group>
          <group group_id="O2">
            <title>Balloon Sinus Dilation Alone</title>
            <description>Successful in-office bilateral balloon dilation of the frontal sinus ostia (FSO) without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Patency Rate</title>
          <description>Patency of the frontal recess/frontal sinus ostia (FSO) was evaluated on a 3-point grading scale from 0 to 2, with 0=Patent, 1=Restenosed/partially occluded, and 2=Occluded. The percentage of sinuses with patency grade 0 and 1 was used to calculate the patency rate.</description>
          <population>Outcome analyzed using the intent-to-treat population, which consisted of all randomized subjects and sinuses. Patency grade for 10 sinuses (6 treatment, 4 control) were missing as clinical investigators were unable to view the frontal recess/FSO, reducing the number of evaluable subjects to 44 in the treatment group and 46 in the control group.</population>
          <units>sinus sides</units>
          <param>Count of Units</param>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0391</p_value>
            <p_value_desc>P-value not adjusted for multiplicity.</p_value_desc>
            <method>McNemar</method>
            <method_desc>McNemarâ€™s exact binomial test was employed to obtain the two-sided p-value at alpha level of 0.05.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Score</title>
        <description>Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)</description>
        <time_frame>Day 30</time_frame>
        <population>Inflammation score for 7 sinuses (4 treatment, 3 control) were missing as clinical investigators were unable to view the frontal recess/FSO for 3 treatment and 2 control sinuses, and 1 participant with 1 treatment and 1 control sinuses was lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Placement of Propel Mini Sinus Implant after a successful in-office balloon dilation of the frontal sinus ostia (FSO)</description>
          </group>
          <group group_id="O2">
            <title>Balloon Sinus Dilation Alone</title>
            <description>Successful in-office bilateral balloon dilation of the frontal sinus ostia (FSO) only without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Score</title>
          <description>Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)</description>
          <population>Inflammation score for 7 sinuses (4 treatment, 3 control) were missing as clinical investigators were unable to view the frontal recess/FSO for 3 treatment and 2 control sinuses, and 1 participant with 1 treatment and 1 control sinuses was lost to follow-up.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="32.22"/>
                    <measurement group_id="O2" value="45.8" spread="36.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from enrollment through Day 180 post-procedure.</time_frame>
      <desc>Adverse event data were collected by clinical investigators using MedDRA terms, organized by System Organ Class.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>An intra-patient control design with placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation compared to in-office balloon dilation without implant placement of the contralateral frontal sinus ostia (FSO) assigned to the control group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation of this study design is utilizing an intra-patient control. This precludes evaluation of patient-reported outcomes. However, it also minimizes interpatient variability, and the differences in surgical techniques.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Stambaugh, Vice President of Clinical &amp; Medical Affairs</name_or_title>
      <organization>Intersect ENT, Inc.</organization>
      <phone>650-641-2103</phone>
      <email>jstambaugh@intersectent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

